Marco Meglio

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Aaron Zelikovich, MD. [LISTEN TIME: 18 minutes]

The phase 3 Aspire study of apazunersen did not meet its primary cognition end point or key secondary end point in Angelman syndrome.

The updated guideline offers evidence-graded recommendations on when to start migraine prevention, which medications to choose, and how to manage special populations.

The European Commission approved modified-release carbidopa/levodopa capsules, already available in the US as Crexont, for adults with moderate to severe motor fluctuations.

The chair of the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery discussed the major themes, clinical takeaways, and unanswered questions from the first update to the guideline in a decade.

A case report documented MOG-IgG antibodies in a mother's breast milk following severe MOGAD, though her breastfed infant's serum tested negative.

A phase 1 feasibility trial found that placing GammaTile radiation therapy directly into the surgical cavity during glioblastoma resection sharply reduced rapid early tumor regrowth compared with historical rates, setting up a phase 3 randomized trial.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is pediatric epilepsy care!

The American Heart Association and American Stroke Association have published an updated, comprehensive guideline for adult stroke rehabilitation, replacing the 2016 version with new and revised recommendations spanning the full recovery continuum.

Brian Lin, PhD, Research Director at the Muscular Dystrophy Association, commented on the first-ever clinical trial framework for Charcot-Marie-Tooth disease, what it means for drug developers, and where the field's biomarker and endpoint evidence still needs to grow.

A coalition of Charcot-Marie Tooth patient groups, clinicians, and pharma companies has published the first consensus framework for designing clinical trials in the disease.

The FDA has cleared Roche's Elecsys pTau217, a blood test that uses a single biomarker to both rule in and rule out amyloid pathology in adults being evaluated for Alzheimer disease, across both primary and specialty care settings.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Huntington disease!

AMO Pharma reached agreement with the FDA, UK MHRA, and Health Canada on the design of a registrational study of AMO-02 for congenital myotonic dystrophy type 1, which will use hospitalization as its primary outcome measure.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Pezhman Roohani, MD. [LISTEN TIME: 17 minutes]

Full results from the phase 3 TEMPO-2 trial, published in Lancet Neurology, showed that flexible-dose tavapadon significantly improved motor symptoms and daily function in people with early Parkinson disease.

David Stamler, MD, Chief Executive Officer of Alterity Therapeutics, discusses the FDA's alignment on the pivotal Phase 3 program for ATH434 in multiple system atrophy and what a successful trial could mean for a disease with no approved disease-modifying therapies.

The cerebrovascular neurosurgeon at University Medical Center New Orleans discussed performing the first THUNDERBOLT stroke thrombectomy in the United States and what computer-assisted vacuum thrombectomy offers over traditional aspiration.

Oak Hill Bio announced dosing of the first participant in BEACON, a pivotal phase 3 trial evaluating rugonersen, an antisense oligonucleotide originally developed by Roche, for Angelman syndrome.

The new data from ALKIVIA marks the first phase 3 study to show statistically significant, clinically meaningful improvement in immune-mediated necrotizing myopathy, a subtype with no approved therapy.

A phase 3 trial found that solriamfetol significantly improved wakefulness and reduced excessive daytime sleepiness in Chinese patients with obstructive sleep apnea, with a safety profile consistent with prior studies conducted in Western populations.

A large claims-based cohort study found that two doses of the recombinant zoster vaccine reduced the risk of shingles by 64% to 81% in adults with multiple sclerosis, a population with elevated shingles risk and historically low vaccine uptake.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is acute ischemic stroke!

A large multicenter study found that APOE genotype and a polygenic Alzheimer risk score together predict up to a 10-year difference in disease onset among people carrying an extra copy of the APP gene, whether through an APP duplication or Down syndrome.

The FDA approved Tauklarify (florquinitau F 18 injection), a tau PET imaging agent, for identifying tau neurofibrillary tangle pathology in adults being evaluated for Alzheimer disease.

The FDA has cleared Quantum BioPharma's investigational new drug application for Lucid-MS, allowing the company to begin a phase 2 trial of the first-in-class demyelination-targeting compound in progressive multiple sclerosis.

CurePSP and UCSF announced enrollment of the first participant in the PSP Trial Platform, believed to be the first platform trial ever conducted specifically for progressive supranuclear palsy, designed to test multiple investigational drugs simultaneously.

Ractigen Therapeutics announced completion of enrollment and first dosing across all cohorts of its phase 2 trial of RAG-17, an investigational siRNA therapy for SOD1-mutated ALS, building on phase 1 data recently published in Nature Medicine.

Horacio Kaufmann, MD, Director of the Dysautonomia Center at NYU Langone, discusses the prospective validation of prodromal MSA criteria, how olfactory testing can sharpen specificity, and how close the field is to biomarker-driven early diagnosis.

Annexon reported that all 10 patients in the first US and European cohort of its open-label FORWARD study showed rapid, clinically meaningful improvement in strength within days of a single tanruprubart infusion for Guillain-Barré syndrome.